Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astera Labs filings document a Nasdaq-listed semiconductor connectivity company serving rack-scale AI infrastructure. The company’s Form 8-K reports cover quarterly and annual operating results, product and demand commentary tied to PCIe 6, Scorpio smart fabric switches, signal conditioning and Smart Cable Modules, and material business updates.
ALAB regulatory disclosures also record its common stock listing on the Nasdaq Global Select Market, emerging growth company status, executive officer appointments and compensation arrangements, and material definitive agreements, including customer-linked warrant terms. Proxy materials describe annual meeting proposals, board elections, auditor ratification, executive compensation votes and stockholder voting mechanics.
Astera Labs, Inc. director Manuel Alba reported that entities associated with him executed open-market sales of 183,000 shares of Astera Labs common stock on April 1, 2026. The trades were carried out automatically under a Rule 10b5-1 trading plan adopted on May 29, 2025, at weighted-average prices between approximately $105.85 and $111.27 per share.
After these sales, the Alba 2003 Living Trust held 1,424,498 shares, Casa Alameda 2007, LLC held 319,863 shares, Alba’s spouse held 5,000 shares, and he held 2,351 shares directly. The filing notes that Alba disclaims beneficial ownership of the trust and LLC shares beyond any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara sold a total of 10,000 shares of common stock in open-market transactions on April 1, 2026, at weighted average prices ranging from just over $105 to about $111 per share.
The filing notes these sales occurred automatically under a pre-arranged Rule 10b5-1 trading plan adopted on May 29, 2025. Following the transactions, Mazzara continues to hold 118,584 shares of Astera Labs common stock directly.
ALAB related sale notice filed via Form 144. The filing lists 150,000 shares of Common stock proposed for sale, dated 04/01/2026. The securities were acquired privately on 03/21/2018 as a Private Acquisition from Issuer or an Affiliate and the filing shows a dollar amount of $16,440,000.00.
ALAB affiliate intends to sell 33,000 shares. A Form 144 filing lists 33,000 Common shares associated with Morgan Stanley Smith Barney LLC, a proposed aggregate amount of $3,616,800.00, and indicates the securities were privately acquired from the issuer or an affiliate on 11/30/2018. The filing date is 04/01/2026 and the shares are listed for sale on NASDAQ.
ALAB proposed the sale of 170,000 shares of Common Stock under Form 144. The filing lists Morgan Stanley Smith Barney LLC, Executive Financial Services, as the filer and shows the shares were acquired on 03/21/2018 by private acquisition from issuer or an affiliate. The filing records $18,632,000.00 on the securities line and includes an anchor date of 04/01/2026.
Astera Labs Inc Schedule 13G/A amendment: The Vanguard Group reports zero beneficial ownership of Astera Labs common stock following an internal realignment that disaggregated certain subsidiaries' holdings, in accordance with SEC Release No. 34-39538.
The filing states Vanguard’s subsidiaries will report beneficial ownership separately and that Vanguard no longer is deemed to beneficially own the shares previously reported by those units.
Astera Labs filed a shelf registration on Form S-3ASR to register up to 5,578,474 shares of Common Stock for resale by selling stockholder Amazon.com NV Investment Holdings LLC. The prospectus states the company will not receive any proceeds from these resales and that the shares consist of warrants exercisable into Common Stock.
The prospectus notes 1,248,707 shares underlying the warrants were vested and exercisable as of February 28, 2026, and that percentage ownership calculations use 171,246,523 shares outstanding as of that date. The selling stockholder’s post‑offering ownership is shown assuming sale of all registered shares.
Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported that a living trust associated with him sold 157,500 shares of common stock in open-market transactions on March 17, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025.
The sales were executed indirectly through the living trust at weighted-average prices generally between about $125 and $135 per share, in multiple tranches. After these transactions, the filing shows the living trust holding 4,531,732 shares, and it also lists additional indirect holdings in several estate planning trusts and 1,452,739 shares held directly, with Jitendra disclaiming beneficial ownership of the trust-held shares except for any pecuniary interest.
Astera Labs filer submitted a Form 144 for the resale of 281,250 shares of Common Stock, including securities acquired as RSUs on 02/15/25. The filing lists J.P. Morgan Securities LLC as broker-dealer.
The filing also discloses prior sales by the same holder: 94,971 shares sold on 02/17/2026 for $11,758,145.75.
Astera Labs, Inc. director Jack R. Lazar reported an open-market sale of 2,500 shares of Common Stock at $130.0000 per share. The transaction occurred on March 16, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
Following this sale, Lazar directly holds 84,851 shares of Astera Labs Common Stock, so the transaction represents a small portion of his reported holdings and appears to be a routine, pre-planned disposition rather than a discretionary trade.